-
Je něco špatně v tomto záznamu ?
Design, synthesis and biological evaluation of new phthalimide and saccharin derivatives with alicyclic amines targeting cholinesterases, beta-secretase and amyloid beta aggregation
D. Panek, A. Więckowska, T. Wichur, M. Bajda, J. Godyń, J. Jończyk, K. Mika, J. Janockova, O. Soukup, D. Knez, J. Korabecny, S. Gobec, B. Malawska,
Jazyk angličtina Země Francie
Typ dokumentu časopisecké články
- MeSH
- aminy chemie farmakologie MeSH
- amyloidní beta-protein metabolismus MeSH
- cholinesterasy metabolismus MeSH
- ftalimidy chemická syntéza chemie farmakologie MeSH
- hematoencefalická bariéra účinky léků MeSH
- inhibiční koncentrace 50 MeSH
- inhibitory enzymů chemická syntéza chemie farmakologie MeSH
- lidé MeSH
- molekulární struktura MeSH
- patologická konformace proteinů MeSH
- peptidové fragmenty metabolismus MeSH
- racionální návrh léčiv MeSH
- sacharin chemická syntéza chemie farmakologie MeSH
- sekretasy metabolismus MeSH
- systémy cílené aplikace léků MeSH
- vazba proteinů účinky léků MeSH
- vazebná místa MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
The complexity of Alzheimer's disease (AD) calls for search of multifunctional compounds as potential candidates for effective therapy. A series of phthalimide and saccharin derivatives linked by different alicyclic fragments (piperazine, hexahydropyrimidine, 3-aminopyrrolidine or 3-aminopiperidine) with phenylalkyl moieties attached have been designed, synthesized, and evaluated as multifunctional anti-AD agents with cholinesterase, β-secretase and β-amyloid inhibitory activities. In vitro studies showed that the majority of saccharin derivatives with piperazine moiety and one phthalimide derivative with 3-aminopiperidine fragment exhibited inhibitory potency toward acetylcholinesterase (AChE) with EeAChE IC50 values ranging from 0.83 μM to 19.18 μM. The target compounds displayed inhibition of human β-secretase-1 (hBACE1) ranging from 26.71% to 61.42% at 50 μM concentration. Among these compounds, two multifunctional agents (26, [2-(2-(4-benzylpiperazin-1-yl)ethyl)benzo[d]isothiazol-3(2H)-one 1,1-dioxide] and 52, 2-(2-(3-(3,5-difluorobenzylamino)piperidin-1-yl)ethyl)isoindoline-1,3-dione) have been identified. Compound 26 exhibited the highest inhibitory potency against EeAChE (IC50 = 0.83 μM) and inhibitory activity against hBACE1 (33.61% at 50 μM). Compound 52 is a selective AChE inhibitor (IC50 AChE = 6.47 μM) with BACE1 inhibitory activity (26.3% at 50 μM) and it displays the most significant Aβ anti-aggregating properties among all the obtained compounds (39% at 10 μM). Kinetic and molecular modeling studies indicate that 26 may act as non-competitive AChE inhibitor able to interact with both catalytic and peripheral active site of the enzyme.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc17023647
- 003
- CZ-PrNML
- 005
- 20170906131710.0
- 007
- ta
- 008
- 170720s2017 fr f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.ejmech.2016.09.078 $2 doi
- 035 __
- $a (PubMed)27721153
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a fr
- 100 1_
- $a Panek, Dawid $u Department of Physicochemical Drug Analysis, Faculty of Pharmacy, Jagiellonian University Medical College, Kraków, Poland.
- 245 10
- $a Design, synthesis and biological evaluation of new phthalimide and saccharin derivatives with alicyclic amines targeting cholinesterases, beta-secretase and amyloid beta aggregation / $c D. Panek, A. Więckowska, T. Wichur, M. Bajda, J. Godyń, J. Jończyk, K. Mika, J. Janockova, O. Soukup, D. Knez, J. Korabecny, S. Gobec, B. Malawska,
- 520 9_
- $a The complexity of Alzheimer's disease (AD) calls for search of multifunctional compounds as potential candidates for effective therapy. A series of phthalimide and saccharin derivatives linked by different alicyclic fragments (piperazine, hexahydropyrimidine, 3-aminopyrrolidine or 3-aminopiperidine) with phenylalkyl moieties attached have been designed, synthesized, and evaluated as multifunctional anti-AD agents with cholinesterase, β-secretase and β-amyloid inhibitory activities. In vitro studies showed that the majority of saccharin derivatives with piperazine moiety and one phthalimide derivative with 3-aminopiperidine fragment exhibited inhibitory potency toward acetylcholinesterase (AChE) with EeAChE IC50 values ranging from 0.83 μM to 19.18 μM. The target compounds displayed inhibition of human β-secretase-1 (hBACE1) ranging from 26.71% to 61.42% at 50 μM concentration. Among these compounds, two multifunctional agents (26, [2-(2-(4-benzylpiperazin-1-yl)ethyl)benzo[d]isothiazol-3(2H)-one 1,1-dioxide] and 52, 2-(2-(3-(3,5-difluorobenzylamino)piperidin-1-yl)ethyl)isoindoline-1,3-dione) have been identified. Compound 26 exhibited the highest inhibitory potency against EeAChE (IC50 = 0.83 μM) and inhibitory activity against hBACE1 (33.61% at 50 μM). Compound 52 is a selective AChE inhibitor (IC50 AChE = 6.47 μM) with BACE1 inhibitory activity (26.3% at 50 μM) and it displays the most significant Aβ anti-aggregating properties among all the obtained compounds (39% at 10 μM). Kinetic and molecular modeling studies indicate that 26 may act as non-competitive AChE inhibitor able to interact with both catalytic and peripheral active site of the enzyme.
- 650 _2
- $a aminy $x chemie $x farmakologie $7 D000588
- 650 _2
- $a sekretasy $x metabolismus $7 D053829
- 650 _2
- $a amyloidní beta-protein $x metabolismus $7 D016229
- 650 _2
- $a vazebná místa $7 D001665
- 650 _2
- $a hematoencefalická bariéra $x účinky léků $7 D001812
- 650 _2
- $a cholinesterasy $x metabolismus $7 D002802
- 650 _2
- $a systémy cílené aplikace léků $7 D016503
- 650 _2
- $a racionální návrh léčiv $7 D015195
- 650 _2
- $a inhibitory enzymů $x chemická syntéza $x chemie $x farmakologie $7 D004791
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a inhibiční koncentrace 50 $7 D020128
- 650 _2
- $a molekulární struktura $7 D015394
- 650 _2
- $a peptidové fragmenty $x metabolismus $7 D010446
- 650 _2
- $a ftalimidy $x chemická syntéza $x chemie $x farmakologie $7 D010797
- 650 _2
- $a patologická konformace proteinů $7 D066263
- 650 _2
- $a vazba proteinů $x účinky léků $7 D011485
- 650 _2
- $a sacharin $x chemická syntéza $x chemie $x farmakologie $7 D012439
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Więckowska, Anna $u Department of Physicochemical Drug Analysis, Faculty of Pharmacy, Jagiellonian University Medical College, Kraków, Poland.
- 700 1_
- $a Wichur, Tomasz $u Department of Physicochemical Drug Analysis, Faculty of Pharmacy, Jagiellonian University Medical College, Kraków, Poland.
- 700 1_
- $a Bajda, Marek $u Department of Physicochemical Drug Analysis, Faculty of Pharmacy, Jagiellonian University Medical College, Kraków, Poland.
- 700 1_
- $a Godyń, Justyna $u Department of Physicochemical Drug Analysis, Faculty of Pharmacy, Jagiellonian University Medical College, Kraków, Poland.
- 700 1_
- $a Jończyk, Jakub $u Department of Physicochemical Drug Analysis, Faculty of Pharmacy, Jagiellonian University Medical College, Kraków, Poland.
- 700 1_
- $a Mika, Kamil $u Department of Physicochemical Drug Analysis, Faculty of Pharmacy, Jagiellonian University Medical College, Kraków, Poland.
- 700 1_
- $a Janockova, Jana $u Biomedical Research Centre, University Hospital Hradec Kralove, Czech Republic.
- 700 1_
- $a Soukup, Ondrej $u Biomedical Research Centre, University Hospital Hradec Kralove, Czech Republic.
- 700 1_
- $a Knez, Damijan $u Department of Pharmaceutical Chemistry, Faculty of Pharmacy, University of Ljubljana, Ljubljana, Slovenia.
- 700 1_
- $a Korabecny, Jan $u Biomedical Research Centre, University Hospital Hradec Kralove, Czech Republic.
- 700 1_
- $a Gobec, Stanislav $u Department of Pharmaceutical Chemistry, Faculty of Pharmacy, University of Ljubljana, Ljubljana, Slovenia.
- 700 1_
- $a Malawska, Barbara $u Department of Physicochemical Drug Analysis, Faculty of Pharmacy, Jagiellonian University Medical College, Kraków, Poland. Electronic address: mfmalaws@cyf-kr.edu.pl.
- 773 0_
- $w MED00001628 $t European journal of medicinal chemistry $x 1768-3254 $g Roč. 125, č. - (2017), s. 676-695
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/27721153 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20170720 $b ABA008
- 991 __
- $a 20170906132309 $b ABA008
- 999 __
- $a ok $b bmc $g 1239328 $s 984560
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2017 $b 125 $c - $d 676-695 $e 20160926 $i 1768-3254 $m European journal of medicinal chemistry $n Eur J Med Chem $x MED00001628
- LZP __
- $a Pubmed-20170720